← Back to Clinical Trials
Recruiting NCT07336394

NCT07336394 Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07336394
Status Recruiting
Phase
Sponsor Chinese Academy of Medical Sciences, Fuwai Hospital
Condition Danon Disease
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2010-01-01
Primary Completion 2028-12-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2010-01-01 with a primary completion date of 2028-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies. These are uncommon conditions where the heart muscle becomes stiff, thick, or enlarged, making it harder for the heart to pump blood. Because they are rare, they can be difficult to diagnose and manage. The investigators are testing new, advanced ways of using a heart scan called a Cardiac Magnetic Resonance (CMR). Participants can think of a CMR as a very powerful camera that takes detailed pictures of their heart without using radiation. What is the study trying to learn? Better Diagnosis: The investigators want to see if these new scanning techniques can help us identify these rare heart conditions more clearly and accurately. This means patients could get a correct diagnosis sooner. Personalized Risk Assessment: The investigators want to see if the scan can help us understand the future risk for each patient better. For example, can it help predict which patients are more likely to have a heart rhythm problem or need specific treatments? This helps doctors create a care plan that is tailored just for participants. What does this mean for participants? If participants choose to take part, they will undergo a CMR scan that uses these new techniques. By participating, they will be helping us find better ways to diagnose and care for people with their condition in the future. The goal is to turn uncertainty into clearer, more personalized information for patients and families.

Eligibility Criteria

Inclusion Criteria: * Patients who have received a cardiac magnetic resonance examination since 2010 and have a suspicion of rare cardiomyopathy. Exclusion Criteria: * Severe arrhythmia; * Severe primary cardiac valvular disease; * Refuse to participate in the study.

Contact & Investigator

Central Contact

Minjie Lu MD, PhD

✉ coolkan@163.com

📞 01088396941

Frequently Asked Questions

Who can join the NCT07336394 clinical trial?

This trial is open to participants of all sexes, studying Danon Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07336394 currently recruiting?

Yes, NCT07336394 is actively recruiting participants. Contact the research team at coolkan@163.com for enrollment information.

Where is the NCT07336394 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT07336394 clinical trial?

NCT07336394 is sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology